Phase 2 Adebrelimab Clinical Trials
6 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–6 of 6 trials
Recruiting
Phase 2
Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
AdebrelimabAdenocarcinoma of GE JunctionAdenocarcinoma of Stomach
Beijing Friendship Hospital49 enrolled1 locationNCT07353684
Recruiting
Phase 2
Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE
Cholangiocarcinoma CancerAdebrelimab (SHR-1316)
The First Affiliated Hospital with Nanjing Medical University122 enrolled4 locationsNCT06607276
Recruiting
Phase 2
Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma
Hepatocellular CarcinomaAdebrelimab
Tianjin Medical University Cancer Institute and Hospital40 enrolled4 locationsNCT06405061
Recruiting
Phase 2
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
Adebrelimab (SHR-1316)XELOXGC/GEJC
Tianjin Medical University Cancer Institute and Hospital25 enrolled1 locationNCT06506292
Recruiting
Phase 1Phase 2
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
Metastatic Pancreatic CancerAdebrelimab (SHR-1316)Decitabine
Tianjin Medical University Cancer Institute and Hospital20 enrolled1 locationNCT06454448
Recruiting
Phase 2
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Hepatocellular CarcinomaBevacizumabAdebrelimab+2 more
The First Affiliated Hospital of Xiamen University71 enrolled1 locationNCT05970666